Patents by Inventor Paul R. Hinton
Paul R. Hinton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8604177Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: March 8, 2011Date of Patent: December 10, 2013Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20110183412Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.Type: ApplicationFiled: March 31, 2010Publication date: July 28, 2011Applicant: Facet Biotech CorprationInventors: Paul R. Hinton, Naoya Tsurushita
-
Publication number: 20110165066Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: March 8, 2011Publication date: July 7, 2011Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Patent number: 7915388Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: September 7, 2007Date of Patent: March 29, 2011Assignee: Abbott LaboratoriesInventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Patent number: 7851600Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.Type: GrantFiled: October 16, 2006Date of Patent: December 14, 2010Assignees: Progenics Pharmaceuticals Inc., Facet Biotech CorporationInventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
-
Publication number: 20100196315Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: ApplicationFiled: April 19, 2010Publication date: August 5, 2010Applicant: ABBOTT LABORATORIESInventors: Susan E. LACY, Emma FUNG, Jonathan P. BELK, Richard W. DIXON, Michael ROGUSKA, Paul R. HINTON, Shankar KUMAR
-
Patent number: 7732570Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.Type: GrantFiled: May 14, 2007Date of Patent: June 8, 2010Assignee: Facet Biotech CorporationInventors: Paul R. Hinton, Naoya Tsurushita
-
Patent number: 7700739Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: GrantFiled: June 29, 2006Date of Patent: April 20, 2010Assignee: Abbott LaboratoriesInventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Publication number: 20100047245Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.Type: ApplicationFiled: June 29, 2006Publication date: February 25, 2010Inventors: Susan E. Lacy, Emma Fung, Jonathan P. Belk, Richard W. Dixon, Michael Roguska, Paul R. Hinton, Shankar Kumar
-
Patent number: 7666419Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.Type: GrantFiled: October 16, 2006Date of Patent: February 23, 2010Assignees: Progenics Pharmaceuticals Inc., Facet Biotech CorporationInventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximillano Vasquez
-
Publication number: 20090232801Abstract: The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.Type: ApplicationFiled: May 29, 2008Publication date: September 17, 2009Applicant: ABBOT LABORATORIESInventors: Heinz Hillen, Stefan Barghorn, Ulrich Ebert, Andreas R. Striebinger, Patrick Keller, Boris Labkovsky, Paul R. Hinton, Veronica M. Juan
-
Publication number: 20090175847Abstract: The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.Type: ApplicationFiled: May 29, 2008Publication date: July 9, 2009Applicant: ABBOTT LABORATORIESInventors: Stefan Barghorn, Ulrich Ebert, Heinz Hillen, Patrick Keller, Andreas R. Striebinger, Boris Labkovsky, Paul R. Hinton, Veronica M. Juan
-
Publication number: 20080287657Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.Type: ApplicationFiled: May 14, 2007Publication date: November 20, 2008Applicant: PDL BioPharma, Inc.Inventors: Paul R. Hinton, Naoya Tsurushita
-
Publication number: 20080226632Abstract: The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.Type: ApplicationFiled: May 23, 2007Publication date: September 18, 2008Applicant: PDL BIOPHARMA, INC.Inventors: Nicholas F. Landolfi, Naoya Tsurshita, Paul R. Hinton, Shankar Kumar
-
Publication number: 20080171014Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: September 7, 2007Publication date: July 17, 2008Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20080107595Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii), two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.Type: ApplicationFiled: October 16, 2006Publication date: May 8, 2008Inventors: William C. Olson, Paul J. Maddon, Naoya Tsurushita, Paul R. Hinton, Maximiliano Vasquez
-
Patent number: 7361740Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.Type: GrantFiled: April 9, 2004Date of Patent: April 22, 2008Assignee: PDL BioPharma, Inc.Inventors: Paul R. Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez
-
Patent number: 7223393Abstract: The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.Type: GrantFiled: February 6, 2004Date of Patent: May 29, 2007Assignee: PDL Biopharma, IncInventors: Nicholas F. Landolfi, Naoya Tsurushita, Paul R. Hinton, Shankar Kumar
-
Patent number: 7217798Abstract: The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.Type: GrantFiled: October 15, 2004Date of Patent: May 15, 2007Assignee: PDL BioPharma, Inc.Inventors: Paul R. Hinton, Naoya Tsurushita
-
Patent number: 7217797Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.Type: GrantFiled: October 15, 2003Date of Patent: May 15, 2007Assignee: PDL Biopharma, Inc.Inventors: Paul R. Hinton, Naoya Tsurushita, J. Yun Tso, Maximiliano Vasquez